Ribo Officially Integrated into Stock Connect Southbound Trading Link, Embarking on a New Chapter in Capital Markets

September 7, 2026·Hong Kong, China

Suzhou Ribo Life Science Co., Ltd. ("Ribo" or the "Company", 06938.HK) is pleased to announce the Company's stock has been officially included in the list of eligible securities of the Southbound Trading Link of the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Scheme ("Stock Connect Scheme"), with effect from today.

The inclusion in the Stock Connect Scheme represents a significant milestone in Ribo's capital market journey, as well as an important step toward the Company's deep integration into both Mainland and international capital markets, and its commitment to supporting the national strategy for high-quality development of the biomedical industry. This inclusion fully reflects the strong endorsement from the capital markets for Ribo's core value, corporate governance standards and growth potential. Following the implementation of Stock Connect Scheme, it is expected to significantly improve the Company's share liquidity, broaden its shareholder base, and enhance the visibility and influence in the capital markets.